Mustang Bio, Inc.
2 Gansevoort Street, 9th floor
New York
New York
10014
United States
Tel: 781-652-4500
Website: http://www.mustangbio.com
Email: info@mustangbio.com
About Mustang Bio, Inc.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies based on the ground breaking Chimeric Antigen Receptor (CAR) research of Dr. Stephen Forman and Dr. Christine Brown of City of Hope, an NCI-designated Comprehensive Cancer Center. Mustang was formed to help bring this pioneering CAR research to as many patients as possible. Mustang, through a research agreement with COH, will develop CARs across multiple cancers, including for AML and Brain Cancer. Both of the lead programs are in phase I clinical trials.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Manuel Litchman
CFO: David Horin
CLINICAL TRIAL:
Please click here for clinical trial information.
112 articles with Mustang Bio, Inc.
-
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8/11/2022
Mustang Bio, Inc. announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.
-
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
7/27/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the first patient successfully received LV-RAG1 ex vivo lentiviral gene therapy to treat recombinase-activating gene-1 (“RAG1”) severe combined immunodeficiency.
-
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
6/22/2022
Mustang Bio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to MB-106, Mustang’s CD20-targeted, autologous CAR T cell therapy for the treatment of Waldenstrom macroglobulinemia, a rare type of B-cell non-Hodgkin lymphoma.
-
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
6/13/2022
Mustang Bio, Inc. announced that updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety profile, high overall response and complete response rates, and CAR T persistence in patients with follicular lymphoma.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
5/19/2022
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107.
-
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
5/12/2022
Mustang Bio, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.
-
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
5/12/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that results from the follicular lymphoma (“FL”) cohort of the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”) were selected for an oral presentation at the European Hematology Association 2022 Hybrid Congress.
-
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
5/3/2022
Mustang Bio, Inc. today announced that interim Phase 1/2 data on treatment with the same lentiviral vector used in MB-107.
-
A roundup of last week's top clinical trial updates and news.
-
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
4/25/2022
Mustang Bio, Inc. today announced updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).
-
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
4/21/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
4/13/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced its plan to initiate a Phase I clinical trial combining CAR T cells and oncolytic virus for the treatment of recurrent glioblastoma (rGBM), supported by interim data from two ongoing investigator-sponsored Phase 1 clinical trials evaluating two clinical candidates, MB-108 (C134 oncolytic virus) and MB‐101.
-
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
4/4/2022
Mustang Bio, Inc. today announced that members of Mustang’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022.
-
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
3/23/2022
Mustang Bio, Inc. today announced financial results and recent corporate highlights for the full year ended December 31, 2021.
-
Mustang Bio to Participate in Three March 2022 Investor Conferences
3/10/2022
Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022.
-
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
3/9/2022
Mustang Bio, Inc. announced that an abstract reporting on Phase 1 trials being conducted at the UAB and City of Hope of Mustang Bio’s exclusively licensed oncolytic viral and CAR T-cell therapies for the treatment of patients with glioblastoma, has been selected as a late-breaking poster presentation at the AACR Annual Meeting 2022, taking place April 8 – 13, 2022, in New Orleans, Louisiana.
-
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
3/8/2022
Mustang Bio, Inc. today announced completion of a $75 million long-term debt facility with Runway Growth Capital LLC ("Runway"), a leading provider of growth loans to both venture and non-venture backed companies.